The Real Drivers of GLP-1 Growth

GLP-1 therapies are poised for massive expansion, with a projected $190 billion peak market (bull case: $240 billion) driven by low current penetration—only 6% of eligible U.S. patients use them. Five catalysts are accelerating adoption: oral formulations, Medicare access, falling out-of-pocket costs, global expansion, and therapeutic innovation beyond weight loss. The ripple effects could reduce U.S. calorie consumption by 1% by 2035, reshaping consumer and healthcare markets.

Understand the structural drivers behind the $190B GLP-1 market opportunity and how access, innovation, and policy are converging to reshape chronic disease treatment.

1. 01Only 6% of eligible U.S. obesity patients currently use GLP-1s, signaling vast untapped demand despite recent growth.
2. 02Oral GLP-1 therapies are driving market expansion, with nearly 80% of users being new to the category.
3. 03Medicare reforms and declining out-of-pocket costs (down to $120/month) are broadening access, with employer coverage expected to reach 65% by 2027.